February 25, 2019 / 6:30 AM / 3 months ago

RPT-Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

(Repeats to attach to earlier alerts)

PARIS, Feb 25 (Reuters) - French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen’s portfolio of products treating rare diseases.

Ipsen said it would buy all of Clementia’s shares for $25.00 each in cash upfront and offer a contingent value right (CVR) purchase of $6.00 per share, giving a total transaction value of up to $1.31 billion. (Reporting by Sudip Kar-Gupta; Editing by Gopakumar Warrier)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below